



PTO/SB/08a (01-08)

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/652,864-Conf. #1487	
			Filing Date	August 29, 2003	
			First Named Inventor	Heinz Kohler	
			Art Unit	1643	
			Examiner Name	A. Gussow	
Sheet	1	of	7	Attorney Docket Number	IXS-10002/49

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-6,566,338	05-20-2003	Weber et al.	
	AB*	US-5,807,746	09-15-1998	Lin et al.	
	AC*	US-6,620,782	09-16-2003	Cai et al.	
	AD*	US-6,596,693	07-22-2003	Keana et al.	
	AE*	US-6,312,694	11-06-2001	Thorpe et al.	
	AF*	US-6,287,537	09-11-2001	Kaminski et al.	
	AG*	US-6,426,413	07-30-2002	Wannamaker et al.	
	AH*	US-6,228,603	05-08-2001	Reed et al.	
	AI*	US-6,821,274	11-23-2004	McHale et al.	
	AJ*	US-6,762,045	07-13-2004	Krebs et al.	
	AK*	US-6,432,680	08-13-2002	Lin et al.	
	AL*	US-6,248,558	06-19-2001	Lin et al.	
	AM*	US-5,219,996	06-15-1993	Bodmer et al.	
	AN*	US-5,191,066	03-02-1993	Bieniarz et al.	
	AO*	US-6,218,160	04-17-2001	Duan	
	AP*	US-6,716,410	04-06-2004	Witztum et al.	
	AQ*	US-6,780,605	08-24-2004	Frostegard et al.	
	AR*	US-20030143226	07-31-2003	Kobayashi et al.	
	AS*	US-20050033033	02-10-2005	Kohler et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-9620219	07-04-1996	Univ Kentucky et al.		
	BB	WO-9617625	06-13-1996	Lynxvale Ltd et al.		
	BC	WO-9914244	03-25-1999	Kohler Heinz		
	BD	WO-06119291	11-09-2006	InNexus Biotechnology Inter- national Limited		
	BE	WO-03080115	10-02-2003	Bipha Corporation		
	BF	WO-0160866	08-27-2001	Brooks et al.		
	BG	WO-02097041	12-05-2002	Kohler et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/652,864-Conf. #1487	
			Filing Date	August 29, 2003	
			First Named Inventor	Heinz Kohler	
			Art Unit	1643	
			Examiner Name	A. Gussow	
Sheet	2	of	7	Attorney Docket Number	IXS-10002/49

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AT*	US-5,276,170	01-04-1994	Kirk et al.	
	AU*	US-5,596,081	01-21-1997	Haley et al.	
	AV*	US-5,563,046	10-08-1996	Mascarenhas et al.	
	AW*	US-5,645,835	07-08-1997	Fell, Jr. et al.	
	AX*	US-5,698,679	12-16-1997	Nemazee	
	AY*	US-5,763,733	06-09-1998	Whitlow et al.	
	AZ*	US-5,811,265	09-22-1998	Quertermous et al.	
	AA1*	US-5,908,626	06-01-1999	Chang et al.	
	AB1*	US-5,969,109	10-19-1999	Bona et al.	
	AC1*	US-6,008,319	12-28-1999	Epstein et al.	
	AD1*	US-6,117,656	09-12-2000	Seed	
	AE1*	US-5,668,255	09-16-1997	Murphy	
	AF1*	US-6,121,424	09-19-2000	Whitlow et al.	
	AG1*	US-6,132,992	10-17-2000	Ledbetter et al.	
	AH1*	US-6,207,804	03-27-2001	Huston et al.	
	AI1*	US-6,224,870	05-01-2001	Segal	
	AJ1*	US-5,314,995	05-24-1994	Fell, Jr. et al.	
	AK1*	US-5,677,171	10-14-1997	Hudziak et al.	
	AL1*	US-6,043,339	03-28-2000	Lin et al.	
	AM1	US-6,316,003	11-13-2001	Frankel et al.	
	AN1	US2005/0287154	12-29-2005	Kohler et al.	
	AO1	US2003/148265	08-07-2003	Brooks et al.	
	AP1	US2006/233790	10-19-2006	Futaki et al.	
	AQ1	US2002/143142	10-03-2002	Lin et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/652,864-Conf. #1487	
			Filing Date	August 29, 2003	
			First Named Inventor	Heinz Kohler	
			Art Unit	1643	
			Examiner Name	A. Gussow	
Sheet	3	of	7	Attorney Docket Number	IXS-10002/49

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CA	Binder, M., F. Otto, R. Mertelsmann, H. Veelken, and M. Trepel. "The epitope recognized by rituximab." Blood 2006, vol. 108, no. 6, pp.1975-1978.		
	CB	Braendstrup, P., O.W. Bjerrum, O.J. Nielsen, B.A. Jensen, N.T. Clausen, P.B. Hansen, I. Andersen, K. Schmidt, T.M. Andersen, N.A. Peterslund, H.S. Birgens, T. Plesner, B.B. Pedersen, and H.C. Hasselbalch. "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Treatment for Adult Refractory Idiopathic Thrombocytopenic Purpura." American Journal of Hematology 2005, vol. 78, pp. 275-280.		
	CC	Burton, C., R. Kaczmarek, R. Jan-Mohamed. "Interstitial Pneumonitis Related to Rituximab Therapy." The New England Journal of Medicine 2003, vol. 348, no. 26, pp. 2690-2691.		
	CD	Edwards, J.C.W., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens, and T. Shaw. "Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis." The New England Journal of Medicine 2004, vol. 350, no. 25, pp. 2572-2581.		
	CE	Pandey, R.N., L.E. Davis, B. Anderson, and P.F. Hollenberg. "Photochemical linking of primary aromatic amines to carrier proteins to elicit antibody response against the amine haptens." Journal of Immunological Methods 1986, vol. 94, pp. 237-246.		
	CF	Lambris, J.D., V.S. Ganu, S. Hirani, and H.J. Muller-Eberhard. "Mapping the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement." Proceedings of the National Academy of Sciences USA 1985, vol. 82, pp. 4235-4239.		
	CG	Frankel, A.E. "Antibody-Toxin Hybrids: A Clinical Review of Their Use." Journal of Biological Response Modifiers 1985, vol. 4, pp. 437-446.		
	CH	Chaddock, J.A., L.M. Roberts, B. Jungnickel, and J. Michael Lord. "A hydrophobic region of ricin a chain which may have a role in membrane translocation can function as an efficient noncleaved signal peptide." Biochemical and Biophysical Research Communications 1995, vol. 217, no. 1, pp. 68-73.		
	CI	Morris, K.N. and I.G. Wool. "Analysis of the contribution of an amphiphilic α -helix to the structure and to the function of ricin A chain." Proceedings of the National Academy of Sciences USA 1994, vol. 91, pp. 7530-7533.		
	CJ	Kohler, H., G. Pavlinkova, K. Rajagopalan, H-T. Wang, S. Chatterjee, and B. Haley. "Specific photoaffinity-labeling locus on antibodies: use for chelation, protein conjugation and gene delivery." Journal of Cellular Biochemistry Supplement, Abstract T029, no. 18D, 1994, pp. 189.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete If Known		
			Application Number	10/652,864-Conf. #1487	
			Filing Date	August 29, 2003	
			First Named Inventor	Heinz Kohler	
			Art Unit	1643	
			Examiner Name	A. Gussow	
Sheet	4	of	7	Attorney Docket Number	IXS-10002/49

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CK	Pavlinkova, G., K. Rajagopalan, S. Muller, A. Chavan, G. Sievert, D. Lou, C. O'Toole, B. Haley, and H. Kohler. "Site-specific photobiotinylation of immunoglobulins, fragments and light chain dimers." <i>Journal of Immunological Methods</i> 1997, vol. 201, pp. 77-88.		
	CL	Miles, E.W. and R.S. Phillips. "Photoinactivation and Photoaffinity Labeling of Tryptophan Synthase $\alpha_2\beta_2$ Complex by the Product Analogue 6-Azido-L-tryptophan." <i>Biochemistry</i> 1985, vol. 24, pp. 4694-4703.		
	CM	Rousselot, P., E. Mappus, T. Blachere, M. Rolland de Ravel, C. Grenot, C. Tonnelles, and C.Y. Cuilleron. "Specific Photoaffinity Labeling of Tyr-49 on the Light Chain in the Steroid-Combining Site of a Mouse Monoclonal Anti-Estradiol Antibody Using Two Epimeric 6 α - and 6 β -(5-Azido-2-nitrobenzoyl)amidoestradiol Photoreagents." <i>Biochemistry</i> 1997, vol. 36, pp. 7860-7868.		
	CN	Fleet, G.W.J., J.R. Knowles, and R.R. Porter. "The Antibody Binding Site: Labelling of a Specific Antibody Against the Photo-Precursor of an Aryl Nitrene." <i>Biochemistry Journal</i> 1972, vol. 128, pp. 499-508.		
	CO	Lou, D. and H. Kohler. "Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide." <i>Nature Biotechnology</i> 1998, vol. 16, pp. 458-462.		
	CP	Demoliou, C.D. and R.M. Epand. "Synthesis and Characterization of a Heterobifunctional Photoaffinity Reagent for Modification of Tryptophan Residues and its Application to the Preparation of a Photoreactive Glucagon Derivative." <i>Biochemistry</i> 1980, vol. 19, pp. 4539-4546.		
	CQ	Foxwell, B.M.J., W.C.J. Ross, and P.E. Thorpe. "Antibody-Ricin Conjugates: A Method of Linkage which Blocks the Galactose Binding Site of Ricin." <i>Behring Institute Mitteilungen</i> 1984, no. 74, pp. 101-107.		
	CR	Tao, M-H. and R. Levy. "Idiotypic/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell Lymphoma." <i>Nature</i> 1993, vol. 362, pp. 755-758.		
	CS	Johnston, A., G.R. Auda, M.A. Kerr, M.W. Steward, and K. Whaley. "Dissociation of primary antigen-antibody bonds is essential for complement mediated solubilization of immune precipitates." <i>Molecular Immunology</i> 1992, vol. 29, no. 5, pp. 659-665.		
	CT	Thorpe, P.E. and W.C.J. Ross. "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates." <i>Immunological Review</i> 1982, vol. 62 pp. 119-158.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/652,864-Conf. #1487
				Filing Date	August 29, 2003
				First Named Inventor	Heinz Kohler
				Art Unit	1643
				Examiner Name	A. Gussow
				Attorney Docket Number	IXS-10002/49
Sheet	5	of	7		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CU	Zhao, Y., T.L. Brown, H. Kohler, and S. Muller. "MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis." Apoptosis 2003, vol. 8, pp. 631-637.		
	CV	Hallbrink, M., A. Floren, A. Elmquist, M. Pooga, T. Bartfai, U. Langel. "Cargo delivery kinetics of cell-penetrating peptides." Biochimica et Biophysica Acta 2001, vol. 1515, pp. 101-109.		
	CW	Soomets, U., M. Lindgren, X. Gallet, M. Hallbrink, A. Elmquist, L. Balaspiri, M. Zorko, M. Pooga, R. Brasseur, U. Langel. "Deletion analogues of transportan." Biochimica et Biophysica Acta 2000, vol. 1467, pp. 165-176.		
	CX	Fischer, P.M., N.Z. Zhelev, S. Wang, J.E. Melville, R. Fahraeus, D.P. Lane. "Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin." Journal of Peptide Research 2000, vol. 55, pp. 163-172.		
	CY	Lindberg, M., J. Jarvet, U. Langel, and A. Graslund. "Secondary Structure and Position of the Cell-Penetrating Peptide Transportan in SDS Micelles As Determined by NMR." Biochemistry 2001, vol. 40, pp. 3141-3149.		
	CZ	Li, Y. R. V. Rosal, P.W. Brandt-Rauf, and R.L. Fine. "Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide." Biochemical and Biophysical Research Communications 2002, vol. 298, pp. 439-449.		
	CA1	Zanetti, M. "Antigenized antibodies." Nature 1992, vol. 355, pp. 476-477.		
	CB1	Zaghouani, H., S.A. Anderson, K.E. Sperber, C. Daian, R.C. Kennedy, L. Mayer, and C.A. Bona. "Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein." Proceedings of the National Academy of Science USA 1995, vol. 92, pp. 631-635.		
	CC1	Kang, C., H. Cheng, S. Rudikoff, and H. Kohler. "Idiotypic self binding of a dominant germline idiotype (T15)." Journal of Experimental Medicine 1987, vol. 165, pp. 1332-1343.		
	CD1	Yan, X., S.V. Evans, M.J. Kaminski, S.D. Gillies, R.A. Reisfeld, A.N. Houghton, and P.B. Chapman. "Characterization of an Ig V _H Idiotype That Results in Specific Homophilic Binding and Increased Avidity for Antigen." The Journal of Immunology 1996, vol. 157, pp. 1582-1588.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/652,864-Conf. #1487	
			Filing Date	August 29, 2003	
			First Named Inventor	Heinz Kohler	
			Art Unit	1643	
			Examiner Name	A. Gussow	
			Attorney Docket Number	IXS-10002/49	
Sheet	6	of	7		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CE1	Dempsey, P.W., M.E.D. Allison, S. Akkaraju, C.C. Goodnow, D.T. Fearon. "C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity." Science 1996, vol. 271, pp. 348-350.		
	CF1	Antoni, G., R. Presentini, F. Perin, A. Tagliabue, P. Ghiara, S. Censini, G. Volpini, L. Villa, and D. Boraschi. "A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity." The Journal of Immunology 1986, vol. 137, pp. 3201-3204.		
	CG1	Bhattacharya-Chatterjee, M., S. Mukerjee, W. Biddle, K.A. Foon, and H. Kohler. "Murine monoclonal anti-idiotypic antibody as a potential network antigen for human carcinoembryonic antigen." The Journal of Immunology 1990, vol. 145, pp. 2758-2765.		
	CH1	Foon, K., M. Chakraborty, W.J. John, A. Sherratt, H. Kohler, and M. Bhattacharya-Chatterjee. "Immune Response to the Carcinoembryonic Antigen in Patients Treated with an Anti-Idiotypic Antibody Vaccine." Journal of Clinical Investigation 1995, vol. 96, pp. 334-342.		
	CI1	Kaminski, M.S., K. Kitamura, and D.G. Maloney, and R. Levy. "Idiotypic Vaccination Against Murin B cell Lymphoma. Inhibition of Tumor Immunity by Free Idiotypic Protein." The Journal of Immunology 1987, vol. 138, pp. 1289-1296.		
	CJ1	Abaza, M. and M.Z. Atassi. "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin." Journal of Protein Chemistry 1992, vol. 11, pp. 433-444.		
	CK1	Rojas, M. S. Yao, and Y.Z. Lin. "Controlling Epidermal Growth Factor (EGF)-stimulated Ras Activation in Intact Cells by a Cell-permeable Peptide Mimicking Phosphorylated EGF Receptor." The Journal of Biological Chemistry 1996, vol. 271, no. 44, pp. 27456-27461		
	CL1	Gerstmayer, B., U. Altenschmidt, M. Hoffman, and W. Wels. "Costimulation of T Cell Proliferation by a Chimeric B7-2 Antibody Fusion Protein Specifically Targeted to Cells Expressing the erbB2 Proto-Oncogene." Journal of Immunology 1997, vol. 158, pp. 4584-4590.		
	CM1	Allison, A.C. "The Mode of Action of Immunological Adjuvants." Developments in Biological Standardization 1998, vol. 92, pp. 3-11.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/652,864-Conf. #1487	
			Filing Date	August 29, 2003	
			First Named Inventor	Heinz Kohler	
			Art Unit	1643	
			Examiner Name	A. Gussow	
Sheet	7	of	7	Attorney Docket Number	IXS-10002/49

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CN1	Awwad, M., P.G. Strome, S.C. Gilman, H.R. Axelrod. "Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions." Cancer Immunology Immunotherapy 1994, vol. 38, pp. 23-30.		
	CO1	Binder, C.J., S. Horkko, A. Dewan, M. Chang, E.P. Kieu, C.S. Goodyear, P.X. Shaw, W. Palinski, J.L. Witztum, and G.J. Silverman. "Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL." Nature Medicine 2003, vol. 9, pp. 736-743.		
	CP1	Y. Zhao, D. Lou, J. Burke, H. Kohler; "Enhanced Anti-B-Cell Tumor Effects with Anti-CD20 Superantibody," Journal of Immunotherapy, 2002, Vol. 25, No. 1, pp. 57-62		
	CQ1	S. Stein, A. Weiss, K. Adermann, P. Lazarovici, J. Hochman, H. Wellhoner; "A disulfide conjugate between anti-tetanus antibodies and HIV (37-72)Tat neutralizes tetanus toxin inside chromaffin cells," FEBS Letters, 458, 1999, pp. 383-386		
	CR1	M. Rojas, J. Donahue, Z. Tan, Y. Lin; "Genetic engineering of proteins with cell membrane permeability," Nature Biotechnology, Vol. 16, April 1998, pp. 370-75		
	CS1	S. Muller, Y. Zhao, T. Brown, A. Morgan, Jr., H. Kohler; "TransMabs: cell-penetrating antibodies, the next generation," Expert Opinion on Biological Therapy, Feb. 2005, pp. 237-241		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.